iBio (NYSE American:iBio) appointed Robert Lutz as chief financial and business officer (CFBO), effective March 4, 2021.
Mr. Lutz will lead iBio’s finance organization and be responsible for building strong licensing capabilities and the financial planning and analysis function, as well as supporting iBio’s relationships with the investment community.
Mr. Lutz brings more than 25 years of experience to iBio, joining the company most recently from Strongbridge Biopharma, a commercial-stage biopharmaceutical company focused on rare diseases. He served as CFO since August 2019, and prior to that, as chief business officer since October 2014. During his tenure, he led the search, evaluation, contracting, and financing of multiple assets, which proved to be critical growth drivers for Strongbridge.
Before joining Strongbridge, Mr. Lutz spent more than a decade at Shire Pharmaceuticals in leadership positions with global responsibilities, including identifying opportunities for acquisition, licensing, partnership and development for Shire’s largest business unit, neuroscience, and the financial management of approximately $5-billion in revenue for its specialty pharmaceuticals division.
In a statement, Tom Isett, chairman and CEO of iBio, said Mr. Lutz’s “deep experience across corporate finance and business development functions, breadth of public company experience, and demonstrated expertise in building product portfolios is a tremendous fit for iBio as we seek to execute on our new business model.”
Mr. Lutz said there is a “unique opportunity to leverage the strengths of the company’s high-speed, plant-based biopharmaceutical production capabilities across multiple product categories and therapeutic areas.”
